Company Filing History:
Years Active: 2016-2019
Title: Innovations and Contributions of Inventor Anders Bjartell
Introduction
Anders Bjartell is a notable inventor based in Malmö, Sweden. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, his work focuses on developing methods and compounds that can aid in the treatment of prostate cancer.
Latest Patents
Anders Bjartell's latest patents include "Ether analogues of galiellalactone" and "Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients." The first patent discloses ether analogues of galiellalactone, methods for preparing these analogues, and their use in cancer treatment. The second patent relates to a Wnt5a protein or peptide that possesses Wnt5a signaling properties, particularly for patients who have undergone or will undergo radical prostatectomy. This invention also includes a method for determining a prognosis for prostate cancer patients based on the evaluation of Wnt5a protein levels in patient samples.
Career Highlights
Throughout his career, Anders has worked with various companies, including Wntresearch AB and Glactone Pharma Development AB. His work in these organizations has allowed him to advance his research and contribute to the development of innovative cancer treatments.
Collaborations
Anders Bjartell has collaborated with notable colleagues such as Tommy Andersson and Johansson Martin. These collaborations have played a crucial role in enhancing his research and expanding the impact of his inventions.
Conclusion
Anders Bjartell's contributions to cancer treatment through his patents and collaborations highlight his dedication to innovation in the medical field. His work continues to pave the way for advancements in the treatment of prostate cancer.